LAUSANNE, Switzerland, July 13, 2026
Vandria announced new Phase 1 clinical data demonstrating that its investigational small molecule VNA-318 successfully translated its preclinical mechanism of action into human biology, supporting continued clinical development for Alzheimer’s disease. The findings were presented at the Alzheimer’s Association International Conference (AAIC) 2026 in London and showed that VNA-318 produced measurable pharmacodynamic effects in the human brain following multiple ascending doses while confirming successful penetration into the central nervous system. The results build upon previously reported positive safety, tolerability, pharmacokinetic, and target engagement data, further strengthening the scientific rationale for advancing the once-daily oral therapy into studies involving patients with neurodegenerative diseases. According to the company, the combined evidence demonstrates that the therapy engages its intended biological target and may offer both cognitive and disease-modifying benefits for individuals affected by Alzheimer’s disease and other age-related neurological disorders.
Phase 1 Study Confirms Brain Penetration and Pharmacodynamic Activity
The newly reported data focused on predefined pharmacodynamic endpoints collected during the multiple ascending dose portion of the randomized Phase 1 study involving healthy volunteers. Researchers used quantitative electroencephalography (qEEG) to evaluate brain activity after 12 days of treatment, identifying reductions in alpha-band brain wave activity, a finding consistent with the compound’s expected mechanism and previous preclinical research. Investigators also directly measured VNA-318 concentrations in cerebrospinal fluid (CSF), confirming that the investigational therapy successfully crossed the blood-brain barrier and reached pharmacologically active levels within the central nervous system. Experts presenting the data noted that the observed qEEG changes may reflect alterations in attention, inhibitory control, and cognitive function, providing important early evidence that the drug is biologically active in the human brain. These findings provide critical clinical validation that VNA-318’s mechanism translates effectively from laboratory models into humans.
Biomarker Results Support Novel Mitochondrial Therapeutic Strategy
Beyond its direct effects on brain activity, additional exploratory analyses identified favorable changes in plasma and intracellular metabolic biomarkers associated with energy metabolism and fatty acid oxidation, biological pathways that have been strongly linked to neurodegenerative disease progression. The biomarker profile closely matched findings previously observed in preclinical disease models, providing further evidence that VNA-318 engages biological processes associated with mitochondrial restoration and reduction of chronic neuroinflammation. Earlier topline Phase 1 results, first presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, demonstrated a favorable safety profile with no serious adverse events, no treatment discontinuations due to adverse events, predictable dose-linear pharmacokinetics, and a half-life supporting once-daily oral dosing. Exposure levels achieved during the study were also consistent with concentrations predicted to provide therapeutic benefit based on preclinical models of Alzheimer’s disease, reinforcing confidence in the candidate’s clinical potential.
Advertisement
Vandria Advances First-in-Class Therapy for Neurodegenerative Diseases
The positive Phase 1 findings position VNA-318 as a promising first-in-class oral small molecule targeting mitochondrial dysfunction, a key biological hallmark underlying Alzheimer’s disease and several other age-related neurodegenerative disorders. Unlike therapies that primarily target amyloid or tau pathology, VNA-318 is designed to restore mitochondrial function while simultaneously reducing chronic neuroinflammation, potentially addressing multiple drivers of disease progression through a novel mechanism. The completed VNA-318-01 study enrolled 92 healthy male participants and successfully demonstrated safety, pharmacokinetic predictability, brain penetration, and pharmacodynamic activity across ascending dose levels. With encouraging evidence supporting target engagement in humans and biomarkers indicating biological activity consistent with preclinical research, Vandria plans to continue advancing VNA-318 into the next stages of clinical development, with Alzheimer’s disease serving as the initial therapeutic indication. The results reinforce the company’s strategy of developing innovative mitochondrial therapies capable of improving cognitive function while potentially slowing disease progression in patients with neurodegenerative disorders.
Source: Vandria press release
